^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MET expression

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
6d
c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. (PubMed, Front Immunol)
This review also discusses the innovative cancer immunotherapies targeting c-MET, including chimeric antigen receptor (CAR) therapies, monoclonal antibodies, and antibody-drug conjugates, while encouraging the development of a comprehensive strategy that simultaneously tackles immune evasion and enhances anti-tumor efficacy further to improve the clinical prognoses for patients with c-MET-positive malignancies. Despite the challenges and variability in efficacy across different cancer subtypes, continued research into the molecular mechanisms and the development of innovative therapeutic strategies will be crucial.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
9d
Hsa_circ_0009910 knockdown in HeLa cells increases miR‑198 expression levels and decreases c‑Met expression levels and cell viability. (PubMed, Oncol Lett)
The hsa_circ_0009910/miRNA-198/c-Met interaction network affects the viability, but not apoptosis, of HeLa cells. Based on this mechanism, the present study suggests that hsa_circ_0009910 may be a promising biomarker for CC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • MIR198 (MicroRNA 198)
|
MET expression
11d
Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. (PubMed, Mol Cancer)
This study provides compelling evidence for the safety and efficacy of CAR-M therapy in treating pancreatic cancer. The results demonstrate that CAR-M-c-MET significantly suppresses pancreatic cancer progression and enhances the effectiveness of cytotoxic chemotherapy. Remarkably, no discernible side effects occur. Further clinical trials are warranted in human pancreatic cancer patients.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
14d
Deoxycholic acid aggravates necrotizing enterocolitis through downregulation of mesenchymal-epithelial transition factor expression. (PubMed, Braz J Med Biol Res)
These findings indicated that MET mediated STAT3 involvement in intestinal epithelial cell proliferation and migration, demonstrating that the inhibitory effect of DCA on MET disrupted this process. These results elucidated the damaging effects and mechanisms of DCA accumulation in NEC, providing new insights into the use of DCA as a therapeutic target for NEC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
14d
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET exon 14 mutation • MET expression
22d
Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics. (PubMed, Mol Med)
CAR macrophages targeting c-Met represent a promising therapeutic strategy for pancreatic cancer, offering targeted elimination of CSCs and disruption of tumor angiogenesis. This study highlights the potential of single-cell multi-omics in guiding the development of precision immunotherapies.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • FGF2 (Fibroblast Growth Factor 2)
|
MET expression
1m
Saikosaponin-b2 Regulates the Proliferation and Apoptosis of Liver Cancer Cells by Targeting the MACC1/c-Met/Akt Signalling Pathway. (PubMed, Adv Pharmacol Pharm Sci)
Additionally, the suppression of MACC1 activation by SS-b2 resulted in a reduction in the viability and proliferation of HepG2 liver cancer cells, and this reduction was comparable to that by doxorubicin (DOX)...Meanwhile, Annexin V-FITC/PI staining and western blot analysis of cleaved caspase 9 and cleaved caspase 3 demonstrated that SS-b2 induced apoptosis of HepG2 liver cancer cells. These findings provide experimental evidence suggesting that SS-b2 is a promising anticancer agent for liver cancer.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • MACC1 (MET Transcriptional Regulator MACC1) • ANXA5 (Annexin A5) • BAD (BCL2 Associated Agonist Of Cell Death)
|
MET expression
|
doxorubicin hydrochloride
1m
Enhanced tumoricidal activity of PD-1 antibody-secreting c-Met CAR-T cells against pancreatic cancer cells (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
PD-1/c-Met CAR-T cells have higher killing efficiency against pancreatic cancer cells with also higher proliferative activity than c-Met CAR-T cells.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
PD-L1 expression • MET expression
1m
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies. (PubMed, Curr Res Pharmacol Drug Discov)
This review explores the mechanisms by which c-Met contributes to chemoresistance in breast cancer and current challenges in targeting c-Met for breast cancer therapy. It discusses strategies to optimize treatment outcomes, ultimately improving patient prognosis and reducing mortality rates associated with this devastating disease.
Review • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
1m
Evaluation of a Novel MET-Targeting Camelid-Derived Antibody in Head and Neck Cancer. (PubMed, Mol Pharm)
Our preclinical data suggest that the camelid antibody 1E7-Fc could be a potential theranostic agent for HNSCC. Further investigations are warranted to confirm these findings in patients and to evaluate 1E7-Fc as an imaging agent and platform to deliver radionuclide or drug therapy to MET-driven cancers.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET overexpression • MET expression
1m
Targeting c-MET for Endoscopic Detection of Dysplastic Lesions Within Barrett's Esophagus Using EMI-137 Fluorescence Imaging. (PubMed, Clin Cancer Res)
EMI-137 accumulates in dysplastic lesions within BE and in c-MET positive EAC. EMI-137 imaging has potential as a screening and surveillance tool for patients with BE and as a means to detecting dysplasia and EAC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • IL1B (Interleukin 1, beta)
|
MET overexpression • MET expression • MET positive
2ms
Cryotherapy in Nulliparous Women with Dysmenorrhea (clinicaltrials.gov)
P=N/A, N=180, Active, not recruiting, University of Malaga
New trial
|
MET expression
2ms
Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover. (PubMed, Cell Death Discov)
Overall, the research highlights the critical role of targeting c-Met to address osimertinib resistance in NSCLC. By demonstrating the efficacy of xanthohumol in overcoming resistance and enhancing therapeutic outcomes, this study provides valuable insights and potential new strategies for improving the clinical management of NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • ETS1 (ETS Proto-Oncogene 1) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
|
EGFR mutation • MET overexpression • MET expression
|
Tagrisso (osimertinib)
2ms
Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth. (PubMed, Pharmaceuticals (Basel))
Overall, our data indicate that c-MET directly regulates NB growth and 3D spheroid growth, and c-MET inhibition by tivantinib may be an effective therapeutic approach for high-risk NB. Further developing c-MET targeted therapeutic approaches and combining them with current therapies may pave the way for effectively translating novel therapies for NB and other c-MET-driven cancers.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification • MET expression
|
tivantinib (ARQ 197)
2ms
CHRYSALIS-2: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
P1, N=701, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=460 --> 701
Enrollment closed • Enrollment change
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation • EGFR expression + MET expression
|
Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
2ms
ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report. (PubMed, Transl Lung Cancer Res)
A 43-year-old, female diagnosed with T4N3M1c NSCLC harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion variant 1 (EML4-ALK v.1) and TP53 co-mutation, displayed only mixed response after three months and highly symptomatic progression after 6 months of first-line brigatinib treatment. The latter may represent a mechanism of intrinsic ALK-TKI resistance and its recognition by FISH, in NGS-negative cases, may be considered before initiating first-line treatment. This recognition is clinically important as combined therapy with ALK-TKI and MET-inhibitor should be the preferred first-line treatment.
Journal • Metastases
|
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4)
|
TP53 mutation • MET amplification • ALK rearrangement • MET overexpression • ALK fusion • MET expression
|
Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)
2ms
The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets. (PubMed, Curr Cancer Drug Targets)
The expression of the PD-L1 and MET genes is remarkably associated with worse tumor clinicopathologic features and poor prognosis in patients with breast cancer. Further investigations using combination drug regimens targeting PD-L1 and MET are important, particularly in breast tumors expressing high levels of both proteins.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • HER-2 positive • PD-L1 overexpression • MET overexpression • HR negative • MET expression • HER-2 negative + HR negative + PD-L1 expression • HER-2 positive + HR negative • HR negative + HER-2 positive
2ms
A Phase I Study of SCC244 in Patients With Advanced MET Alterations Solid Tumors (clinicaltrials.gov)
P1, N=177, Completed, Haihe Biopharma Co., Ltd. | Unknown status --> Completed | N=75 --> 177
Trial completion • Enrollment change • Metastases
|
MET amplification • MET overexpression • MET expression
|
Haiyitan (gumarontinib)
2ms
Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression. (PubMed, Mol Oncol)
Finally, by performing a comparative transcriptomic analysis, we identify target genes that could play a relevant role in these cellular processes. Thus, our results demonstrate for the first time in prostate cancer models a functional interaction between ETS transcription factors (ETV1 and ERG) and MET signalling that confers more aggressive properties and highlight a molecular signature characteristic of this combined action.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • ETV1 (ETS Variant Transcription Factor 1)
|
MET expression
|
Tabrecta (capmatinib)
3ms
Selective inhibition of cancer cell migration using a pH-responsive nucleobase-modified DNA aptamer. (PubMed, Chem Sci)
CSL1-II in a weakly acidic environment had a stronger inhibitory effect on the HGF/c-Met pathway and exerted a strong controlling effect on the spreading and migration of cancer cells. Our strategy provides a simple and versatile method to develop pH-responsive DNA aptamers and represents the first example of a cancer-selective c-Met antagonist that inhibits cell migration.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
3ms
TYRO3 and EPHA2 Expression Are Dysregulated in Breast Cancer. (PubMed, Cell Biochem Funct)
EPHA2 expression is also related to aging and smoking habits. The expression levels of the TAM and EPHA2 genes seem to play an important role in breast cancer, being also influenced by the patient's lifestyle.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • EPHA2 (EPH receptor A2) • TYRO3 (TYRO3 Protein Tyrosine Kinase)
|
MET expression
3ms
PREGMOUV: Physical Activity and Sedentary Behavior During Pregnancy (clinicaltrials.gov)
P=N/A, N=630, Recruiting, University Hospital, Clermont-Ferrand | Not yet recruiting --> Recruiting
Enrollment open
|
MET expression
3ms
Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model. (PubMed, Mol Biomed)
Importantly, rAd.mDCN.mCD40L and rAd.mCD40L prevented tumor liver metastasis much more effectively than rAd.Null and rAd.mDCN. Therefore, rAd.mDCN.mCD40L and rAd.mCD40L are promising approaches for CRC therapy.
Preclinical • Journal • Oncolytic virus • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase) • CD40LG (CD40 ligand)
|
MET overexpression • MET expression
3ms
R5093-ONC-1863: A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=231, Active, not recruiting, Regeneron Pharmaceuticals | N=82 --> 231 | Trial completion date: Oct 2024 --> Jan 2032 | Trial primary completion date: Oct 2024 --> Jan 2032
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation
|
davutamig (REGN5093)
3ms
c-MET is an important marker for acid-driven metastasis and anti-immune in colorectal cancer. (PubMed, Int Immunopharmacol)
MET is an important contributor to acid-driven colorectal cancer metastasis and participates in immune escape of colorectal cancer. It is of great significance for the prognosis and immunotherapy of colorectal cancer and some other cancers.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8)
|
MET expression
3ms
Histopathologic classification and immunohistochemical features of papillary renal neoplasm with potential therapeutic targets. (PubMed, J Pathol Transl Med)
Also, there were some cases showing STING expression and those cases were associated with increased Ki-67 proliferation index (marginal significance, p = .063). Our findings suggested that there are subsets of pRCC with c-MET, p16, c-MYC, and STING expression and those cases could be potential candidates for targeted therapy.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FH (Fumarate Hydratase) • STING (stimulator of interferon response cGAMP interactor 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PRCC (Proline Rich Mitotic Checkpoint Control Factor)
|
MET expression • MYC expression
3ms
PREGMOUV: Physical Activity and Sedentary Behavior During Pregnancy (clinicaltrials.gov)
P=N/A, N=630, Not yet recruiting, University Hospital, Clermont-Ferrand
New trial
|
MET expression
5ms
Intrinsic ALK-TKI Resistance Due to Met-Coamplification in ALK+ NSCLC, Effectively Treated by Alectinib-crizotinib Combination (IASLC-WCLC 2024)
Yet, to our knowledge, we present herein the first case of ALK + NSCLC rapidly progressing on 1 st line Brigatinib treatment due to de novo MET- amplification. The recognition of this mechanism of ALK-TKI resistance by FISH, especially in NGS-negative cases, should be considered before initiating 1 st line treatment. This is of clinical importance, as effective combined therapy with ALK-TKI and MET-inhibitor is feasible.
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4)
|
TP53 mutation • MET amplification • ALK rearrangement • MET overexpression • EML4-ALK fusion • ALK fusion • MET expression • ALK amplification • TP53 G245S
|
Oncomine™ Comprehensive Assay v3M • Archer® FusionPlex® Lung Kit • FusionPlex® Dx
|
Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)
7ms
New P1/2 trial
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation
|
davutamig (REGN5093)
7ms
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer. (PubMed, Lung Cancer)
Capmatinib plus nivolumab showed clinical activity and manageable safety in pretreated patients with advanced EGFR wild-type NSCLC, independent of MET status.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR wild-type • MET exon 14 mutation • MET expression
|
Opdivo (nivolumab) • Tabrecta (capmatinib)
7ms
Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications. (PubMed, Sci Rep)
NGS results highlighted underlying genetic heterogeneity within samples, which may have a confounding influence on the expression of a particular biomarker. T-TMAs, integrated with quantitative biomarker digital scoring, are useful tools to identify hallmark specific expression of biomarkers in pancreatic cancer.
Retrospective data • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • TGFB1 (Transforming Growth Factor Beta 1)
|
MET expression • IDO1 expression
7ms
AHNAK2 Promotes the Progression of Pancreatic Ductal Adenocarcinoma by Maintaining the Stability of c-MET. (PubMed, Cancer Manag Res)
Mechanistically, AHNAK2 promoted tumor progression by preventing c-MET degradation and persistently activating the HGF/c-MET signaling pathway. Overall, our study revealed that AHNAK2 plays an important role in PDAC progression by modulating the c-MET signaling pathway, and targeting AHNAK2 may be an effective therapeutic strategy for PDAC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • AHNAK2 (AHNAK Nucleoprotein 2)
|
MET expression
8ms
hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma: in-silico and in-vitro study. (PubMed, EXCLI J)
Compared to temozolomide, the combined treatment significantly decreased CDK4, CDK6, CCND1, and MMP2 expression. hsa-miR-34a-5p targets RAF1, as the signaling factor of the MAPK pathway, and potentiates the temozolomide anti-tumoral effect on A172 cells.
Preclinical • Journal
|
PD-L1 (Programmed death ligand 1) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • MIR34A (MicroRNA 34a-5p) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)
|
MET expression • CCND1 expression • CDK6 expression
|
temozolomide
8ms
Expressions and Clinical Significance of Met and YAP in Gastric Cancer Tissue Microarray. (PubMed, Gastroenterol Res Pract)
The expressions of Met and YAP are closely associated with the survival outcomes as well as clinicopathological features in patients with gastric cancer. Moreover, our findings highlight that Met serves as an independent prognostic factor for gastric cancer.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression • CD133 expression
8ms
PAPMET: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed (clinicaltrials.gov)
P2, N=152, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2023 --> Dec 2024 | Trial primary completion date: Oct 2020 --> Oct 2023
Trial completion date • Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET mutation • MET expression
|
Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)
8ms
Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET. (PubMed, J Exp Clin Cancer Res)
Our results demonstrate that MSLN plays a critical role in BM of NSCLC by modulating the JNK/MET signaling network and thus, provides a potential novel therapeutic target for preventing BM in NSCLC patients.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • MSLN (Mesothelin) • MAPK8 (Mitogen-activated protein kinase 8)
|
MET expression • MSLN expression
|
Xalkori (crizotinib) • Tabrecta (capmatinib)
9ms
CHRYSALIS: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=751, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Jun 2025
Trial completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
9ms
HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors. (PubMed, Transl Lung Cancer Res)
Combination treatment with lorlatinib and erlotinib significantly reduced HRG1-induced activation of RTK signaling in ALK-positive NSCLC cells. HER3 overexpression has potential as a prognostic marker in ALK-positive NSCLCs, including ALK-TKI naïve and treated cases, especially those with EML4-ALK V1/V2. Assessing HER3 expression may be crucial for treatment planning and outcome prediction in these patients.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 expression • ALK positive • EGFR overexpression • MET overexpression • EML4-ALK fusion • ALK fusion • ERBB3 expression • MET expression • ERBB3 overexpression • EML4-ALK fusion + ALK positive • EML4-ALK variant 1
|
erlotinib • Lorbrena (lorlatinib)
9ms
Prediction of MET Overexpression in Lung Adenocarcinoma from Hematoxylin and Eosin Images. (PubMed, Am J Pathol)
This model was evaluated on an independent holdout test set of 300 over-expressed and 289 normal patients, demonstrating an ROC-AUC of 0.70 (95th percentile interval: 0.66 - 0.74) with stable performance characteristics across different patient clinical variables and robust to synthetic noise on the test set. These results suggest that H&E-based predictive models could be useful to prioritize patients for confirmatory testing of MET protein or MET gene expression status.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET overexpression • MET expression
9ms
PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells. (PubMed, Int J Mol Sci)
Importantly, genetic ablation of c-Met caused the reduced growth of HSC-3 cells and decreased Src phosphorylation and HIF-1α expression. Together, these results demonstrate that c-Met is highly activated in HSC-3 human oral cancer cells, and PHA exhibits strong antigrowth, proapoptotic, and antiangiogenic effects on these cells, which are mediated through regulation of the phosphorylation and expression of multiple targets, including c-Met, Src, PKB, mTOR, Mcl-1, and HIF-1α.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
MET expression • MCL1 expression • HIF1A expression
|
PHA665752
9ms
Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy. (PubMed, Cancer Treat Res Commun)
Overall, the c-MET x CD137 BsAb exhibits a promising developability profile as a tumor-targeted immune agonist by minimizing off-target effects while effectively delivering immune agonism. It has the potential to overcome resistance to anti-PD-(L)1 therapies.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
MET expression
|
Keytruda (pembrolizumab) • utomilumab (PF-05082566) • urelumab (BMS-663513)
9ms
Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway. (PubMed, Can Respir J)
Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. Furthermore, MET overexpression reversed the inhibitory effect of anlotinib on the DDP resistance of NSCLC cells, and this effect could be eliminated by MCL-1 knockdown or ACT001 (an inhibitor for STAT3/Akt pathway). Our results confirmed that anlotinib inhibited DDP resistance in NSCLC cells, which might decrease MCL-1 expression via mediating the MET/STAT3/Akt pathway.
Journal
|
MCL1 (Myeloid cell leukemia 1)
|
MET overexpression • MET expression • MCL1 expression • STAT3 expression
|
cisplatin • Focus V (anlotinib) • dimethylamino micheliolide (ACT001)